Credit: Canva
Prostate cancer may return after treatment in anywhere from 30,000 to 50,000 people each year. As a result, researchers are looking for better ways to treat the disease when it recurs. A trial led by Ravi A. Madan, M.D., Senior Clinician in the Genitourinary Malignancies Branch, is studying hormone blocking therapy and immunotherapy without testosterone suppression for patients with biochemically recurrent prostate cancer and a positive PSMA scan.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, please contact Amy R. Hankin, PA-C at (240) 858 3149 or amy.hankin@nih.gov
Clinicaltrials.gov identifier: NCT06096870
NCI Protocol ID: IRB001556
Official Title: Phase II Trial of Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow, treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
